In order to raise cash to progress its clinical developments, TorreyPines Therapeutics is disposing its Alzheimer’s developments through two recently signed deals. The beneficiaries are Eisai, which has acquired the genetics programme, and QR Pharma, which has licensed worldwide rights to three compounds, Posiphen™, bisnorcymcerine and phenserine.